HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

E 6010

cysteine 84 in the epidermal growth factor domain is replaced by serine

Also Known As:

E-6010; E6010

Networked: 8 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kitamura , N: 1 article (10/2000)
2.	Kunitomo , R: 1 article (10/2000)
3.	Moriyama , S: 1 article (10/2000)
4.	Okamoto , K: 1 article (10/2000)
5.	Sun , L B: 1 article (10/2000)
6.	Tagami , H: 1 article (10/2000)
7.	Utoh , J: 1 article (10/2000)

Related Diseases

1.	Myocardial Infarction 06/01/1997 - "The efficacy of E6010 was compared with that of native t-PA in 199 patients with acute myocardial infarction who were treated within 6 h of onset in a prospective, randomized, double-blind multicenter trial. " 06/01/1997 - "A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. " 06/01/1997 - "This prospective, randomized, double-blind multicenter trial evaluated the efficacy and safety of a single bolus injection of the novel modified tissue-type plasminogen activator (t-PA) E6010 in the treatment of acute myocardial infarction compared with that of native t-PA. "
2.	Infarction (Infarctions) 06/01/1997 - "The present study indicates that, compared with native t-PA, a single bolus injection of E6010 over 2 min produces a higher rate of early recanalization of the infarct-related coronary artery without fatal bleeding complications." 04/01/1995 - "Left ventricular ejection fraction and regional wall motion (expressed as the infarction chord number; ie, the number of chords < -2SD among chords 12-66) were 42 +/- 5% and 5 +/- 3, respectively, in the E6010 group, 31 +/- 8% and 16 +/- 12 in the rt-PA group, and 31 +/- 2% and 32 +/- 13 in the urokinase group 1 h after reperfusion, indicating earlier recovery of left ventricular function after thrombolysis in the E6010 group than in the rt-PA and urokinase groups (**p < 0.01 vs control). "
3.	Hemorrhage 07/01/1994 - "These changes were not so marked with administration of E6010, and therefore we concluded that E6010 is unlikely to cause bleeding complications after administration." 06/01/1997 - "The present study indicates that, compared with native t-PA, a single bolus injection of E6010 over 2 min produces a higher rate of early recanalization of the infarct-related coronary artery without fatal bleeding complications."
4.	Coronary Thrombosis 03/01/1992 - "This study was conducted to compare the thrombolytic effect of a novel modified tissue plasminogen activator, E6010, with that of recombinant human tissue plasminogen activator (t-PA), administered by single intravenous bolus injection in pigs with occlusive coronary thrombosis. " 03/01/1992 - "Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig." 09/01/1994 - "In a canine copper coil-induced coronary thrombosis model, the differences in frequency of reperfusion arrhythmias (premature ventricular complexes: PVC) and mortality rate after thrombolysis by intravenous bolus injection of a novel modified tissue-type plasminogen activator (t-PA), E6010, and by continuous intravenous infusion of native t-PA or urokinase were evaluated. "
5.	Pulmonary Hypertension 10/01/2000 - "The present study indicated that E6010 more rapidly reduced pulmonary hypertension in our APTE model. "

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	Copper
3.	Urokinase-Type Plasminogen Activator (Urokinase)
4.	Polyvinyl Chloride (PVC)

Related Therapies and Procedures

1.	Intravenous Infusions